The EVEREST project is set to push the is set to push the frontiers of biomedical research by exploring the transformative potential of extracellular vesicles (EVs). EVs are small particles that act as messengers between cells which could transform early diagnosis and targeted treatments for diseases such as cancer and cardiovascular conditions.
The project, funded through the Marie Skłodowska-Curie Actions (MSCA) programme under Horizon Europe GA101183034, has a budget of €1,311,000 and will run for 48 months, starting in January 2025.
FOx BIOSYSTEMS supports this interdisciplinary collaboration with its WHITE FOx real-time sensing platform that provides integrated quantification and EV isolation to accelerate biomarker discovery and analysis.
For more information about the EVEREST consortium, please visit the EU Cordis website.
The EIC Accelerator is a funding programme under Horizon Europe that offers support to start-ups and SMEs that have an innovative product, service or business model that could create new markets or disrupt existing ones in Europe and even worldwide,
On December 20th, 2022 FOx BIOSYSTEMS was awarded an EIC accelerator grant for their ambitious project to bring to market a combined quantification and isolation application for extracellular vesicles (EVs) unlocking their great potential in diagnostic applications.
The EIC grant will enable FOx BIOSYSTEMS to launch a collection of EV applications on their system to the market in 2024, three years sooner than previously planned. This will cover an array of application-specific sensors, protocols, and workflow support with immediate potential impact on ongoing and new research programs.
* Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EIC. Neither the European Union nor the granting authority can be held responsible for them.
The MeBioS (Mechatronics, Biostatistics and Sensors) division at the University of Leuven in Belgium first began investigating fiber-optic biosensing based on surface plasmon resonance in 2006 and named it FO-SPR. The technology quickly attracted national and international funding, along with winning first place in the Battle of Talents competition for young entrepreneurs in Belgium.
FOx BIOSYSTEMS was founded in 2017 by Filip Delport and Jeroen Lammertyn as a spin-off from MeBioS and still maintains close collaborations with MeBioS scientists.
The CONSENSE project forms part of the European Commission’s Innovative Training Networks that support joint research training and/or postdoctoral programs. It has been created to stimulate the development of new sensor technologies that can measure a range of biomolecules in blood, with the aim of creating truly personalized medicine and improving patient outcomes.
This approach requires an interdisciplinary (molecular engineering, sensing technology, clinical applications) and intersectoral (academic, hospital, industry) approach by sufficiently high-quality groups, which will be provided by this collaboration. In addition, CONSENSE will secure the competitiveness of European higher education as well as the European medical technology industry, which is an important and innovative sector with high impact for the future.
FOx BIOSYSTEMS will use this funding to investigate the potential of the fiber-optic based surface plasmon resonance technology for continuous immune monitoring of patients in critical care settings. This will be of great benefit in the emerging field of novel cancer immunotherapies since it will allow the early detection and timely treatment of severe complications such as cytokine release syndrome.
Historic Collaborations & Projects
